Whatâs funny about this is you couldnât even be troubled to actually highlight a specific research publication here - you just copied a link to a PubMed search of the term âmedistemâ (which returns 20 results).
To the layperson: Impressive! There are published articles! Research! Science!
To the scientist: letâs take a look at these âstudiesâ and see what weâre working with.
The search for âMedistemâ returns 20 hits. A handful of them have literally nothing to do with stem-cell research (e.g. âA novel method of modifying immune responses by vaccination with lipiodol-siRNA mixturesâ). Another handful are not âoriginal researchâ studies but basically opinion pieces or proposals for ideas based on theoretical explanations (e.g. âTherapeutic use of Aldara in chronic myeloid leukemiaâ - if you actually click on that article, youâll notice that itâs not a study of results achieved with that therapy, but rather a proposition for âHey maybe we could try thisâ - the same is true of âStem cell therapy for autismâ and a few others). Several of these are case reports (i.e. âWe saw this interesting case, tried this thingy and hereâs what happenedâ) rather than outcomes research. One study was basically a âPhase 1â study (âFeasibility investigation of allogeneic endometrial regenerative cellsâ) where stem cells were given to 4 patients with multiple sclerosis and there were no reported adverse events in short-term treatment - this is the type of early-stage research that is used to justify performing a larger study.
Iâve stated several times in this thread that I have no specific axe to grind with stem cells, but I appreciate the necessity of following our present scientific process (Phase 1 trials for safety and dose-finding; Phase 2 trials for dose-finding and early-stage efficacy; Phase 3 trials for longer-term understanding of safety, adverse events, and clinical effectiveness) which you are either incapable of or unwilling to understand.
Cell therapy is not my area of expertise, but design and analysis of clinical trials is. I am happy to break down any studies on the subject. But most of what youâre posting has not advanced to the stage of clinical-outcomes research. There are a lot of studies that are basically âthis is how we grow stem cellsâ or âhereâs a population where stem cells might workâ and (from what youâve posted so far) little research demonstrating safety and efficacy of stem cell treatment. There are a few applications where it has proven effective; there are others where it was been insufficiently studied; and there are still others where it has been studied and, to date, has shown no benefit.
A few months ago, there was a Cochrane review that thoroughly reported on âStem cell therapy for chronic ischaemic heart disease and congestive heart failure.â
The Cochrane findings acknowledge that some of the results are promising but also criticize the studies for major methodological issues (such as a lack of blinding and/or randomization). Their conclusion is as follows:
âThis systematic review and meta-analysis found low-quality evidence that treatment with bone marrow-derived stem/progenitor cells reduces mortality and improves left ventricular ejection fraction over short- and long-term follow-up and may reduce the incidence of non-fatal myocardial infarction and improve New York Heart Association (NYHA) Functional Classification in people with chronic ischaemic heart disease and congestive heart failure. These findings should be interpreted with caution, as event rates were generally low, leading to a lack of precision.â